EASIEEnvironment for Application Software Integration and Execution
EASIEEdinburgh Area Scouts International Expeditions (UK)
References in periodicals archive ?
Global and diversified healthcare company Sanofi (Euronext:SAN) (NYSE:SNY) on Saturday announced that data from the EASIE (Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-Naive Patients) study showed that people with early type 2 diabetes uncontrolled on metformin demonstrated superior HbA1c (glycated haemoglobin) reduction with Lantus (insulin glargine [rDNA origin] injection) versus sitagliptin.
The data from the EASIE study was presented at the American Diabetes Association 72nd Scientific Sessions.
EASIE was a multicentre, international, randomised, open-label, six-month study that compared once-daily insulin glargine with sitagliptin (100 mg) once daily, as add-on therapy to metformin, in insulin-naive people with early type 2 diabetes (median disease duration after diagnosis: 4.